{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:44:24Z","timestamp":1762641864569},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor family, has been identified as a critical regulator of bone resorption. Considering the possible role of OPG in rheumatoid arthritis (RA) and in the osteoclastogenesis suppression effects of statins, the present study aims to investigate the effects of fluvastatin on serum levels OPG and disease activity score (DAS) in patients with RA. Forty patients with RA were randomized in a placebo\u2010controlled trial to receive 40 mg fluvastatin or placebo as an adjunct to existing disease\u2010modifying antirheumatic drug (DMARD) therapy (methotrexate, leflunomide, hydroxychloroquine). Patients were followed up over 12 weeks. OPG and disease activity variables were measured at baseline and after 12 weeks of treatment. After 12 weeks, the OPG level was significantly increased in the fluvastatin group compared to the placebo group. DAS\u201028 was significantly decreased in the fluvastatin group compared to the placebo group. C\u2010reactive protein (CRP), morning stiffness, swollen joint count (SJC), and tender joint count (TJC) were significantly decreased in the fluvastatin group compared to the placebo group; however, erythrocyte sedimentation rate (ESR), modified health assessment questionnaire (MHAQ), and visual analogue screen (VAS) were not changed significantly. In conclusion, fluvastatin administration could increase the OPG levels and improve disease activity variables in patients with RA. Therefore, fluvastatin may serve a potential benefit in the treatment of RA patients.<\/jats:p>","DOI":"10.1002\/jcph.725","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T09:50:36Z","timestamp":1456134636000},"page":"1272-1276","source":"Crossref","is-referenced-by-count":3,"title":["A Clinical Study Evaluating the Effects of Fluvastatin on Serum Osteoprotegerin Levels in Rheumatoid Arthritis Patients"],"prefix":"10.1002","volume":"56","author":[{"given":"Sahar Kamal","family":"Hegazy","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Faculty of Pharmacy Tanta University  Tanta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa El\u2010Morsy Abd","family":"El\u2010Ghany El\u2010Sayed","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine Rheumatology &amp; Rehabilitation Faculty of Medicine Tanta University  Tanta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa El\u2010Saeed","family":"El\u2010Hefnawy","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Tanta University  Tanta Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(01)00682-2"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2007.10.013"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.2005.10719466"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64417-3"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11487"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10680"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0646"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2008.12.004"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2003.10.005"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050601"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0014"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-005-0005-5"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080109"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11150"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10388"},{"key":"e_1_2_5_18_1","first-page":"426","article-title":"Tumor necrosis factor\u2010alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts","volume":"31","author":"Kubota A.","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(88)90002-1"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.15106"},{"key":"e_1_2_5_21_1","first-page":"124","article-title":"Non\u2010lipid actions of statins","volume":"6","author":"Tandon V","year":"2004","journal-title":"JK Science"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-870538"},{"key":"e_1_2_5_23_1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1160\/TH06-11-0648","article-title":"Effects of hypolipemic drugs on the osteoprotegerin\u2014sRANKL system in patients with coronary artery disease","volume":"97","author":"Celi\u0144ska\u2010L\u00f6wenhoff M","year":"2007","journal-title":"Thromb Haemostas"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0003319708330525"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.08.012"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_2_5_27_1","first-page":"705","article-title":"ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology","volume":"26","author":"Gestel AM","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_5_28_1","first-page":"1432","article-title":"Further development of a physical function scale on a multidimensional Health Assessment Questionnaire for standard care of patients with rheumatic diseases","volume":"32","author":"Pincus T","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2011.01302.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20141"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH672>3.0.CO;2-W"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0514-3"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0919"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2012.05.002"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16449-0"},{"issue":"4","key":"e_1_2_5_38_1","first-page":"189","article-title":"A comparative study on atorvastatin versus methotrexate in rheumatoid arthritis in a double blind placebo control trial","volume":"12","author":"Sandooghi M","year":"2011","journal-title":"Shiraz E\u2010Med J"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0589-4"},{"key":"e_1_2_5_40_1","first-page":"326258","article-title":"The role of simvastatin in the therapeutic approach of rheumatoid arthritis","volume":"2013","author":"Cojocaru L","year":"2013","journal-title":"Autoimmune Dis"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000572"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.725","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T18:22:29Z","timestamp":1694888549000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1002\/jcph.725"],"URL":"https:\/\/doi.org\/10.1002\/jcph.725","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,12]]}}}